Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 | P08235 | 8/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 7/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.97 |
| ▸ | PGR | P06401 | 4/20 | 0.89 |
| ▸ | NR3C1 | P04150 | 4/20 | 0.89 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.69 |
| ▸ | MAPT | P10636 | 3/20 | 0.69 |
| ▸ | POLB | P06746 | 1/20 | 0.69 |
| ▸ | GAA | P10253 | 1/20 | 0.69 |
| ▸ | AR | P10275 | 2/20 | 0.69 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.65 |
| ▸ | HPGD | P15428 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | MLNR | O43193 | 1/20 | 0.65 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.65 |
| ▸ | HTT | P42858 | 1/20 | 0.65 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20668516 | 1.00 | NR3C2 (1.00) | NR3C2HIF1AKMT2APGRNR3C1 | |
| SCHEMBL14935923 | 1.00 | NR3C2 (1.00) | NR3C2HIF1AKMT2APGRNR3C1 | |
| SCHEMBL14935780 | 0.99 | NR3C2 (1.00) | NR3C2HIF1AKMT2APGRNR3C1 | |
| SCHEMBL20668513 | 0.99 | NR3C2 (1.00) | NR3C2HIF1AKMT2APGRNR3C1 | |
| SCHEMBL7137194 | 0.99 | NR3C2 (1.00) | NR3C2HIF1AKMT2APGRNR3C1 | |
| SCHEMBL14935882 | 0.99 | NR3C2 (1.00) | NR3C2HIF1AKMT2APGRNR3C1 | |
| SCHEMBL28378823 | 0.99 | NR3C2 (1.00) | NR3C2HIF1AKMT2APGRNR3C1 | |
| SCHEMBL7144935 | 0.99 | NR3C2 (1.00) | NR3C2HIF1AKMT2APGRNR3C1 | |
| SCHEMBL7142707 | 0.99 | NR3C2 (1.00) | NR3C2HIF1AKMT2APGRNR3C1 | |
| SCHEMBL14936016 | 0.99 | NR3C2 (1.00) | NR3C2HIF1AKMT2APGRNR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10188667-B2 | Pharmaceutical compositions and methods of use of 4-pregenen-11β-17-21-triol-3,20-dione derivatives | ALLERGAN, INC. (US) | 2019-01-29 | — | — | US | claimed |
| US-20180147217-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF 4-PREGENEN-11BETA-17-21-TRIOL-3,20-DIONE DERIVATIVES | ALLERGAN INC (US) | 2018-05-31 | — | — | US | claimed |
| US-9717743-B2 | Pharmaceutical compositions and methods of use of 4-pregenen-11β-17-21-triol-3,20-dione derivatives | ALLERGAN, INC. (US) | 2017-08-01 | — | — | US | claimed |
| US-20150005519-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF 4-PREGENEN-11BETA-17-21-TRIOL-3,20-DIONE DERIVATIVES | ALLERGAN, INC. (US) | 2015-01-01 | — | — | US | claimed |
| US-8865691-B2 | Pharmaceutical compositions and methods of use 4-pregenen-11β-17-21-triol-3,20-dione derivatives | ALLERGAN, INC. (US) | 2014-10-21 | — | — | US | claimed |
| US-20130123226-A1 | PHARAMCEUTICAL COMPOSITIONS AND METHODS OF USE 4-PREGENEN-11BETA-17-21-TRIOL-3,20-DIONE DERIVATIVES | ALLERGAN, INC. (US) | 2013-05-16 | — | — | US | claimed |
| US-20080166398-A1 | Sertaconazole and hydrocortisone; for dermal diseases; inflammation | FERRER INTERNACIONAL, S.A. (ES) | 2008-07-10 | — | — | US | claimed |
| EP-1858510-A1 | ANTIFUNGAL COMPOSITIONS COMPRISING SERTACONAZOL AND HYDROCORTISONE AND/OR AN ANTIBACTERIAL QUINOLONE COMPOUND | FERRER INTERNACIONAL, S.A. (ES) | 2007-11-28 | — | — | EP | claimed |
| WO-2006092374-A1 | ANTIFUNGAL COMPOSITIONS COMPRISING SERTACONAZOL AND HYDROCORTISONE AND/OR AN ANTIBACTERIAL QUINOLONE COMPOUND | FERRER INTERNACIONAL, S. A. (ES) | 2006-09-08 | — | — | WO | claimed |
| EP-1698336-A1 | Antifungal compositions comprising Sertaconazole and either Hydrocortisone or an antibacterial agent | FERRER INTERNACIONAL, S.A. (ES) | 2006-09-06 | — | — | EP | claimed |
| US-20240307299-A1 | SELF-EMULSIFYING DRUG DELIVERY (SEDDS) FOR OPHTHALMIC DRUG DELIVERY | ALLERGAN, INC. | 2024-09-19 | — | — | US | disclosed |
| US-20220218599-A1 | SELF-EMULSIFYING DRUG DELIVERY (SEDDS) FOR OPHTHALMIC DRUG DELIVERY | ALLERGAN, INC. | 2022-07-14 | — | — | US | disclosed |
| WO-2019055028-A1 | PARTICLES, COMPOSITIONS, AND METHODS FOR OPHTHALMIC AND/OR OTHER APPLICATIONS | KALA PHARMACEUTICALS, INC. (US) | 2019-03-21 | — | — | WO | disclosed |
| US-10188667-B2 | Pharmaceutical compositions and methods of use of 4-pregenen-11β-17-21-triol-3,20-dione derivatives | ALLERGAN, INC. (US) | 2019-01-29 | — | — | US | disclosed |
| US-20180147217-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF 4-PREGENEN-11BETA-17-21-TRIOL-3,20-DIONE DERIVATIVES | ALLERGAN INC (US) | 2018-05-31 | — | — | US | disclosed |
| WO-2006092374-A1 | ANTIFUNGAL COMPOSITIONS COMPRISING SERTACONAZOL AND HYDROCORTISONE AND/OR AN ANTIBACTERIAL QUINOLONE COMPOUND | FERRER INTERNACIONAL, S. A. (ES) | 2006-09-08 | — | — | WO | disclosed |
| EP-1698336-A1 | Antifungal compositions comprising Sertaconazole and either Hydrocortisone or an antibacterial agent | FERRER INTERNACIONAL, S.A. (ES) | 2006-09-06 | — | — | EP | disclosed |
| EP-1308500-A1 | Ophthalmic composition | Menicon Co., Ltd. (JP) | 2003-05-07 | — | — | EP | disclosed |
| US-5489576-A | ADMINISTERING ASCORBIC ACID ALPHA-TOCOPHERYL PHOSPHATE DIESTER | SENJU PHARMACEUTICAL CO., LTD. (JP) | 1996-02-06 | — | — | US | disclosed |
| EP-0661053-A1 | Use of tocopherol ascorbic adic phosphates for hemorrhoidal diseases | Senju Pharmaceutical Co., Ltd. (JP) | 1995-07-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150005519-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF 4-PREGENEN-11BETA-17-21-TRIOL-3,20-DIONE DERIVATIVES | NR3C2, MC2R, NR3C1 | NR3C2 1/4885HIF1A 4264/4885KMT2A 4628/4885 |
| US-20180147217-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF 4-PREGENEN-11BETA-17-21-TRIOL-3,20-DIONE DERIVATIVES | NR3C2, MC2R, NR3C1 | NR3C2 1/4885HIF1A 4264/4885KMT2A 4628/4885 |
| US-20130123226-A1 | PHARAMCEUTICAL COMPOSITIONS AND METHODS OF USE 4-PREGENEN-11BETA-17-21-TRIOL-3,20-DIONE DERIVATIVES | NR3C2, NR3C1, HSD11B2 | NR3C2 1/4885HIF1A 3606/4885KMT2A 4238/4885 |
| US-20220218599-A1 | SELF-EMULSIFYING DRUG DELIVERY (SEDDS) FOR OPHTHALMIC DRUG DELIVERY | LSS, SBDS, SPAST | NR3C2 2701/4885HIF1A 1419/4885KMT2A 4501/4885 |
| US-10188667-B2 | Pharmaceutical compositions and methods of use of 4-pregenen-11β-17-21-triol-3,20-dione derivatives | NR3C2, MC2R, NR3C1 | NR3C2 1/4885HIF1A 4152/4885KMT2A 4615/4885 |
| US-20240307299-A1 | SELF-EMULSIFYING DRUG DELIVERY (SEDDS) FOR OPHTHALMIC DRUG DELIVERY | LSS, SBDS, SPAST | NR3C2 2701/4885HIF1A 1419/4885KMT2A 4501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.